• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VENLAFAXINE Drug Record

  • Summary
  • Interactions
  • Claims
  • VENLAFAXINE chembl:CHEMBL637 Approved

    Alternate Names:

    SUNVENIZ XL
    VAXALIN XL
    VEXARIN XL
    RANFAXINE XL
    EFFEXOR
    ALVENTA XL
    VENLABLUE XL
    EFEXOR
    FORAVEN XL
    TIFAXIN XL
    VENLANEO XL
    RODOMEL XL
    VENSIR XL
    VIEPAX
    MENTAVEN XL
    TONPULAR XL
    BONILUX XL
    VENLADEX XL
    VENAXX XL
    TRIXAT XL
    AMPHERO XL
    DEPEFEX XL
    TARDCAPS XL
    WINFEX XL
    EFEXOR XL
    VENLAFAXINE
    VENLALIC XL
    VIEPAX XL
    POLITID XL
    TREVILOR
    WY-45030
    VENLAFAXIN
    ELAFAX
    EFECTIN
    VENLAFEXINE
    1-[2-(DIMETHYLAMINO)-1-(4-METHOXYPHENYL)ETHYL]CYCLOHEXAN-1-OL
    EFFEXOR®
    rxcui:39786
    drugbank:00285
    pubchem.compound:5656
    chembl:CHEMBL637
    chemidplus:93413-69-5

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant
    Drug Class antidepressive agents, second-generation
    Year of Approval 1993
    (3 More Sources)

    Publications:

    Van Ameringen et al., 2009, Pharmacotherapy for social anxiety disorder: an update., Isr J Psychiatry Relat Sci
    Chen et al., 2005, The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors., Eur Neuropsychopharmacol
    Shang et al., 2007, Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study., J Clin Psychopharmacol
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Malizia et al., 1997, Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo., J. Psychopharmacol. (Oxford)
    Westenberg, 2009, Recent advances in understanding and treating social anxiety disorder., CNS Spectr
    Gould et al., 2006, A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters., Biol. Psychiatry
    Béïque et al., 2000, Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat., Neuropharmacology
    Sindrup et al., 2005, Antidepressants in the treatment of neuropathic pain., Basic Clin. Pharmacol. Toxicol.
    Bymaster et al., 2001, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors., Neuropsychopharmacology
    Marshe VS et al., 2017, Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults., Am J Psychiatry
    Mitchell et al., 2006, The effects of norepinephrine transporter inactivation on locomotor activity in mice., Biol. Psychiatry
    Vaishnavi et al., 2004, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity., Biol. Psychiatry
    Béïque et al., 1998, Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters., Eur. J. Pharmacol.
    Pu M et al., 2013, Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response., Pharmacogenomics
    Millan et al., 2004, S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole., J. Pharmacol. Exp. Ther.
    Tzvetkov MV et al., 2008, Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment., Pharmacogenet Genomics
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
    Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
    Lohoff FW et al., 2013, Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder., Pharmacogenomics J
    Moresco M et al., 2016, Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1., Clin Neuropharmacol
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    Jeleń AM et al., 2015, The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report., Int J Med Sci
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Taranu A et al., 2017, The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings., Basic Clin Pharmacol Toxicol
    Hopkins SC et al., 2013, Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder., Psychiatry Res
    Narasimhan S et al., 2012, Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder., Psychiatry Res
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • VENLAFAXINE   FKBP5

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21449676 20709156 19676097 18597649 17467808 15565110


    Sources:
    PharmGKB

  • VENLAFAXINE   TPH2

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18496129


    Sources:
    PharmGKB

  • VENLAFAXINE   SLC6A2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Effexor
    Novel drug target Established target

    PMIDs:
    28068779 19728573 16893531 14744476 19238127 9669506 10884561 15910402 11750180


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • VENLAFAXINE   SLC6A4

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Effexor
    Novel drug target Established target

    PMIDs:
    19728573 15695064 17224717 9537821 9305421 19238127 16140280 10884561 15910402 11750180


    Sources:
    TdgClinicalTrial TEND

  • VENLAFAXINE   COMT

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28627776 23706899 22417933


    Sources:
    PharmGKB

  • VENLAFAXINE   GRIA3

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23394390


    Sources:
    PharmGKB

  • VENLAFAXINE   HTR1B

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21449676


    Sources:
    PharmGKB

  • VENLAFAXINE   GABRQ

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23394390


    Sources:
    PharmGKB

  • VENLAFAXINE   ABCB1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26757307 26704739 26664259 24192121 22641028 21449676 18215618


    Sources:
    PharmGKB

  • VENLAFAXINE   GABRP

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23394390


    Sources:
    PharmGKB

  • VENLAFAXINE   BDNF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14978196


    Sources:
    NCI

  • VENLAFAXINE   GABRA6

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23394390


    Sources:
    PharmGKB

  • VENLAFAXINE   HTR2A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22006095


    Sources:
    PharmGKB

  • VENLAFAXINE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • VENLAFAXINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TdgClinicalTrial: VENLAFAXINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: VENLAFAXINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1993
    Drug Class antidepressive agents, second-generation

    Publications:

  • NCI: VENLAFAXINE

    • Version: 14-September-2017

    Alternate Names:
    C1278 NCI drug code

    Drug Info:

    Publications:
    Millan et al., 2004, S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole., J. Pharmacol. Exp. Ther.

  • PharmGKB: venlafaxine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tzvetkov MV et al., 2008, Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment., Pharmacogenet Genomics
    Pu M et al., 2013, Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response., Pharmacogenomics
    Marshe VS et al., 2017, Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults., Am J Psychiatry

  • TTD: Venlafaxine

    • Version: 2020.06.01

    Alternate Names:
    D0P1UX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL637

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Venlafaxine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21